Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
ACCENTIA BIOPHARMACEUTICALS INC (ABPI)
|
|
Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
In millions, except per share items | Dec-31-12 | Sep-30-12 | Jun-30-12 | Mar-31-12 | Dec-31-11 | Sep-30-11 | Jun-30-11 | Mar-31-11 |
| 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Cost of goods sold | 105.7% | 222.0% | 80.6% | 65.2% | 51.9% | 147.3% | 58.9% | 53.8% |
Gross profit | -5.7% | -122.0% | 19.4% | 34.8% | 48.1% | -47.3% | 41.1% | 46.2% |
Sales and marketing | 4.8% | 3.6% | 4.0% | 3.6% | 2.2% | 5.2% | 3.5% | 2.4% |
Research and development | 163.9% | 190.7% | 125.3% | 148.3% | 78.0% | 113.9% | 61.6% | 34.2% |
General and administrative | 175.9% | 183.7% | 130.5% | 323.9% | 81.3% | 175.2% | 282.9% | 303.3% |
EBITDA | -342.2% | 205.7% | -235.9% | -3151.5% | -103.0% | -191.2% | -299.2% | -283.8% |
Depreciation | 7.6% | 6.0% | 4.4% | -2707.2% | 2.7% | 4.9% | 2.3% | 1.8% |
EBITA | -349.8% | 199.7% | -240.3% | -444.3% | -105.7% | -196.1% | -301.4% | -285.6% |
Amortization of intangibles | 0.4% | 14.6% | 0.2% | 0.0% | 7.8% | 60.6% | 10.8% | 9.4% |
EBIT | -350.2% | 185.0% | -240.5% | -444.3% | -113.4% | -256.7% | -312.2% | -295.0% |
Pre-tax income | -1590.8% | -1775.1% | 346.8% | -693.7% | 53.6% | -2090.9% | -264.2% | -85.4% |
Income taxes | 0.0% | 87.1% | -25.5% | 0.0% | -35.7% | -0.6% | 5.3% | 0.0% |
Net income | -1590.8% | -617.4% | 346.8% | -512.3% | 53.6% | -1526.2% | -264.2% | -86.7% |
|